2016 American Transplant Congress
Treatment of Post-Transplant Focal Glomerulosclerosis: The Effect on Histopathology Lesions and Podocyte Foot Process Effacement.
Background: Post-transplant Focal Segmental Glomerulosclerosis (FSGS) is associated with increased risk for renal allograft failure. It has been reported in the literature that podocyte foot…2016 American Transplant Congress
The Clinical Differences Between First and Second Kidney Transplant in IgA Nephropathy: A Multicenter Retrospective Study.
Background Recurrent IgA nephropathy (IgAN) after renal transplantation has been reported to range between 12% and 65%. However, few data are available on the second…2016 American Transplant Congress
Comparison of Efficacy of Different Regimens for Treating Recurrent IgA Nephropathy After Kidney Transplantation.
Background Recurrent IgA nephropathy is a common complication after kidney transplantation. How to treat recipients with recurrent IgA nephropathy is still controversial. There are two…2016 American Transplant Congress
Management of Recurrent aHUS After Adult Kidney transplantation Despite Eculizumab Prophylaxis.
Background Eculizumab (EZB) is approved by NHSE in the UK for prevention and managment of recurrent aHUS after kidney transplantation. Purpose We report aggressive recurrence…2016 American Transplant Congress
Thrombotic Microangiopathy After Kidney Transplantation: A Rare but Serious Complication.
Universidade Federal de São Paulo, São Paulo, Brazil.
Purposes: Study the clinical characteristics of cases with thrombotic microangiopathy (TMA) in the renal allograft, identify the triggers of this disease and determine its impact…2016 American Transplant Congress
Tacrolimus Precision Medicine: Antibiotics Increase Intra-Patient Variability in Tacrolimus Trough Concentrations in Kidney Transplant Recipients.
Medicine/Nephrology and Hyeprtension, Weill Cornell Medical College, New York, NY.
BACKGROUND. The gut microbiome impacts drug absorption, metabolism, and distribution and was recently shown to be associated with tacrolimus dosing requirements. Since antibiotics can alter…2016 American Transplant Congress
Standard Dose Valganciclovir Prophylaxis for High-Risk Kidney Transplant Recipients Reduces Incidences of Breakthrough and Resistant Cytomegalovirus Infection.
University of Michigan, Ann Arbor, MI.
Background: Valganciclovir (VGCV) 900 mg/day is the standard dose (SD) for CMV prophylaxis in patients with CrCl > 60 ml/min, although some transplant centers use…2016 American Transplant Congress
Subclinical Cytomegalovirus Viraemia in Renal Transplant Recipients.
Background: Studies suggest low-level cytomegalovirus (CMV) viraemia, detected with sensitive molecular assays, may lead to poorer graft outcomes following renal transplantation.Aims: Investigate the incidence, outcomes,…2016 American Transplant Congress
Is CMV Prophylaxis Effective in CMV-Seropositive Patients Receiving Thymoglobulin as Induction Therapy?
Kidney Transplantation Service, Hospital das Clinicas - University of Sao Paulo, Sao Paulo, Brazil.
Thymoglobulin (ATG) used as induction therapy is considered a risk factor for CMV disease in renal transplantation (RTx) and prophylaxis is recommended. Our center policy…2016 American Transplant Congress
Clinical Measures to Reduce Early Urinary Tract Infections Following Kidney Transplantation: A Single Center Experience.
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA.
Urinary Tract infection (UTI) following kidney transplantation (KTx) is associated with increased morbidity. We implemented simple clinical measures in an attempt to reduce UTI incidence…
American Transplant Congress abstracts